Thursday, June 28, 2012
Derma Sciences Inc., of Princeton, N.J., said results of its Phase II trial testing DSC127 in patients with diabetic foot ulcers will be published in the July 2012 issue of Wound Repair and Regeneration, with data showing preliminary evidence that the drug, a clinical formulation of NorLeu3-A(1,7), is safe and effective in accelerating the healing of diabetic foot ulcers.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.